ClearPoint Neuro, Inc. Common Stock CLPT
i
Market dataready · fetched 2026-11-07T02:06:15.173Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:00.776319751Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T02:06:13.321369+00:00
ClearPoint Neuro, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.18 | 122.1% | 19.8% | |||
| 25Δ | 7.52 | 125.7% | 16.7% | |||
| 30Δ | 11.47 | 206.2% | 40.2% | 7.75 | 120.0% | 14.8% |
| 35Δ | 11.14 | 221.6% | 37.9% | 7.99 | 114.2% | 13.0% |
| 40Δ | 10.43 | 209.5% | 30.6% | 8.22 | 108.4% | 11.1% |
| 45Δ | 8.91 | 91.8% | 9.4% | 8.46 | 102.6% | 9.2% |
| 50Δ | 8.65 | 104.3% | 8.9% | 8.69 | 96.8% | 7.4% |
| 55Δ | 8.40 | 116.8% | 8.3% | 8.93 | 91.0% | 5.5% |
| 60Δ | 8.14 | 129.3% | 7.8% | 9.28 | 94.1% | 4.5% |
| 65Δ | 7.89 | 141.8% | 7.2% | 9.68 | 101.0% | 3.9% |
| 70Δ | 7.63 | 154.2% | 6.7% | 10.09 | 108.0% | 3.4% |
| 75Δ | 7.24 | 169.0% | 5.9% | 10.49 | 114.9% | 2.8% |
| 80Δ | 6.69 | 186.0% | 4.8% | 10.89 | 121.8% | 2.2% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.18
- IV
- 122.1%
- B/E move
- 19.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.52
- IV
- 125.7%
- B/E move
- 16.7%
30Δ
- Pseudo strike
- 11.47
- IV
- 206.2%
- B/E move
- 40.2%
- Pseudo strike
- 7.75
- IV
- 120.0%
- B/E move
- 14.8%
35Δ
- Pseudo strike
- 11.14
- IV
- 221.6%
- B/E move
- 37.9%
- Pseudo strike
- 7.99
- IV
- 114.2%
- B/E move
- 13.0%
40Δ
- Pseudo strike
- 10.43
- IV
- 209.5%
- B/E move
- 30.6%
- Pseudo strike
- 8.22
- IV
- 108.4%
- B/E move
- 11.1%
45Δ
- Pseudo strike
- 8.91
- IV
- 91.8%
- B/E move
- 9.4%
- Pseudo strike
- 8.46
- IV
- 102.6%
- B/E move
- 9.2%
50Δ
- Pseudo strike
- 8.65
- IV
- 104.3%
- B/E move
- 8.9%
- Pseudo strike
- 8.69
- IV
- 96.8%
- B/E move
- 7.4%
55Δ
- Pseudo strike
- 8.40
- IV
- 116.8%
- B/E move
- 8.3%
- Pseudo strike
- 8.93
- IV
- 91.0%
- B/E move
- 5.5%
60Δ
- Pseudo strike
- 8.14
- IV
- 129.3%
- B/E move
- 7.8%
- Pseudo strike
- 9.28
- IV
- 94.1%
- B/E move
- 4.5%
65Δ
- Pseudo strike
- 7.89
- IV
- 141.8%
- B/E move
- 7.2%
- Pseudo strike
- 9.68
- IV
- 101.0%
- B/E move
- 3.9%
70Δ
- Pseudo strike
- 7.63
- IV
- 154.2%
- B/E move
- 6.7%
- Pseudo strike
- 10.09
- IV
- 108.0%
- B/E move
- 3.4%
75Δ
- Pseudo strike
- 7.24
- IV
- 169.0%
- B/E move
- 5.9%
- Pseudo strike
- 10.49
- IV
- 114.9%
- B/E move
- 2.8%
80Δ
- Pseudo strike
- 6.69
- IV
- 186.0%
- B/E move
- 4.8%
- Pseudo strike
- 10.89
- IV
- 121.8%
- B/E move
- 2.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 92.76% | |
| 99.65% | |
| 102.65% | |
| 109.17% | |
| 98.91% | |
| 95.73% | |
| 94.33% | |
| 94.22% | |
| 90.81% | |
| 89.75% | |
| 93.36% | |
| 94.71% | |
| 93.72% | |
| 94.24% | |
| 88.34% | |
| 174.03% | |
| 91.45% | |
| 89.62% | |
| 103.22% | |
| 96.25% | |
| 94.25% | |
| 95.66% | |
| 104.90% | |
| 98.13% | |
| 90.12% | |
| 93.03% | |
| 92.55% | |
| 97.84% | |
| 90.72% | |
| 89.92% | |
| 98.62% | |
| 102.28% | |
| 102.12% | |
| 99.63% | |
| 99.97% | |
| 90.95% | |
| 88.63% |
Medical Devices
CNMD
CONMED Corporation, a medical technology company, develops, manufactures and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company…
More →CTKB
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, delivering innovative cell analysis solutions that advance research in immunology, cancer…
More →CVRX
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
More →DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is…
More →DXCM
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with…
More →ELMD
Description unavailable
More →